Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia

British Journal of Haematology

Volumn 168, Issue 2, 2015, Pages 284-290

  Taher, Ali T ^a   Porter, John B ^b   Viprakasit, Vip ^c   Kattamis, Antonis ^d   Chuncharunee, Suporn ^e   Sutcharitchan, Pranee ^f   Siritanaratkul, Noppadol ^c   Origa, Raffaella ^g   Karakas, Zeynep ^h   Habr, Dany ⁱ   Zhu, Zewen ⁱ   Cappellini, Maria Domenica ^j  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF ATHENS   (Greece)

^e MAHIDOL UNIVERSITY   (Thailand)

^f KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^g Evolutiva/Osp Reg Microcitemie ASL   (Italy)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Chelation therapy; Iron overload; Liver iron concentration; Non transfusion dependent thalassaemia; Serum ferritin

Indexed keywords

DEFERASIROX; FERRITIN; IRON; PLACEBO; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ARTICLE; CHELATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FERRITIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; LIVER LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON TRANSFUSION DEPENDENT THALASSEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THALASSEMIA; ADOLESCENT; ADULT; BLOOD; CLINICAL TRIAL; FEMALE; LIVER; MALE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; BENZOATES; DOUBLE-BLIND METHOD; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; THALASSEMIA; TRIAZOLES; YOUNG ADULT;

EID: 84923800477     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13119     Document Type: Article

References (22)

1. Cheong, J.W., Kim, H.J., Lee, K.H., Yoon, S.S., Lee, J.H., Park, H.S., Kim, H.Y., Shim, H., Seong, C.M., Kim, C.S., Chung, J., Hyun, M.S., Jo, D.Y., Jung, C.W., Sohn, S.K., Yoon, H.J., Kim, B.S., Joo, Y.D., Park, C.Y. & Min, Y.H. (2014) Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. Transfusion, 54, 1542-1551.
2. Eghbali, A., Taherahmadi, H., Shahbazi, M., Bagheri, B. & Ebrahimi, L. (2014) Association between serum ferritin level, cardiac and hepatic T2-star MRI in patients with major beta-thalassemia. Iranian Journal of Pediatric Hematology Oncology, 4, 17-21.
3. Lal, A., Goldrich, M.L., Haines, D.A., Azimi, M., Singer, S.T. & Vichinsky, E.P. (2011) Heterogeneity of hemoglobin H disease in childhood. New England Journal of Medicine, 364, 710-718.
4. Mancuso, A., Sciarrino, E., Renda, M.C. & Maggio, A. (2006) A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin, 30, 119-124.
5. Musallam, K.M., Cappellini, M.D., Wood, J.C., Motta, I., Graziadei, G., Tamim, H. & Taher, A.T. (2011) Elevated liver iron concentration is a marker of increased morbidity in patients with β-thalassemia intermedia. Haematologica, 96, 1605-1612.
6. Musallam, K.M., Motta, I., Salvatori, M., Fraquelli, M., Marcon, A., Taher, A.T. & Cappellini, M.D. (2012) Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with beta-thalassemia intermedia. Blood Cells, Molecules and Diseases, 49, 136-139.
7. Musallam, K.M., Rivella, S., Vichinsky, E. & Rachmilewitz, E.A. (2013a) Non-transfusion-dependent thalassemias. Haematologica, 98, 833-844.
8. Musallam, K.M., Cappellini, M.D. & Taher, A.T. (2013b) Evaluation of the 5 mg/g liver iron concentration threshold and its association with morbidity in patients with beta-thalassemia intermedia. Blood Cells, Molecules and Diseases, 51, 35-38.
9. Musallam, K., Cappellini, M.D., Daar, S., Karimi, M., El-Beshlawy, A., Magestro, M., Wulff, J., Pietri, G. & Taher, A. (2013c) Morbidity risk in untreated patients with β-thalassemia intermedia: a closer look at the role of iron overload. Haematologica, 98 (Suppl. 1), 486-487, abstract S1172.
10. Origa, R., Galanello, R., Ganz, T., Giagu, N., Maccioni, L., Faa, G. & Nemeth, E. (2007) Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica, 92, 583-588.
11. Pakbaz, Z., Fischer, R., Fung, E., Nielsen, P., Harmatz, P. & Vichinsky, E. (2007) Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatric Blood & Cancer, 49, 329-332.
12. Rivella, S. (2012) The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Reviews, 26, S12-S15.
13. St Pierre, T.G., Clark, P.R., Chua-anusorn, W., Fleming, A.J., Jeffrey, G.P., Olynyk, J.K., Pootrakul, P., Robins, E. & Lindeman, R. (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood, 105, 855-861.
14. Taher, A., El Rassi, F., Isma'eel, H., Koussa, S., Inati, A. & Cappellini, M.D. (2008) Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica, 93, 1584-1586.
15. Taher, A.T., Musallam, K.M., El-Beshlawy, A., Karimi, M., Daar, S., Belhoul, K., Saned, M.S., Graziadei, G. & Cappellini, M.D. (2010) Age-related complications in treatment-naive patients with thalassaemia intermedia. British Journal of Haematology, 150, 486-489.
16. Taher, A.T., Porter, J., Viprakasit, V., Kattamis, A., Chuncharunee, S., Sutcharitchan, P., Siritanaratkul, N., Galanello, R., Karakas, Z., Lawniczek, T., Ros, J., Zhang, Y., Habr, D. & Cappellini, M.D. (2012a) Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood, 120, 970-977.
17. Taher, A.T., Porter, J.B., Viprakasit, V., Kattamis, A., Chuncharunee, S., Sutcharitchan, P., Siritanaratkul, N., Galanello, R., Karakas, Z., Lawniczek, T., Habr, D., Ros, J., Zhang, Y. & Cappellini, M.D. (2012b) Estimation of liver iron concentration by serum ferritin measurement in non-transfusion-dependent thalassemia patients: analysis from the 1-year THALASSA study. Haematologica, 97 (Suppl. 2), 383. (abst 0927).
18. Taher, A.T., Vichinsky, E., Musallam, K.M., Cappellini, M.D. & Viprakasit, V. (2013a) Thalassemia International Federation. Guidelines for the management of non-transfusion dependent thalassaemia (NTDT). Available at: http://www.thalassaemia.org.cy/wp-content/uploads/pdf/educational-programmes/Publications/Non-Transfusion%20Dependent%20Thalassaemias%20%282013%29/NTDT%20ENGLISH.pdf.
19. Taher, A.T., Porter, J.B., Viprakasit, V., Kattamis, A., Chuncharunee, S., Sutcharitchan, P., Siritanaratkul, N., Galanello, R., Karakas, Z., Lawniczek, T., Habr, D., Ros, J., Zhu, Z. & Cappellini, M.D. (2013b) Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Annals of Hematology, 92, 1485-1493.
20. Taher, A.T., Porter, J.B., Viprakasit, V., Kattamis, A., Chuncharunee, S., Sutcharitchan, P., Siritanaratkul, N., Origa, R., Karakas, Z., Habr, D., Zhu, Z. & Cappellini, M.D. (2014) Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. European Journal of Haematology, 92, 521-526.
21. Vichinsky, E. (2007) Hemoglobin E syndromes. Hematology American Society of Hematology Education Program, 79-83.
22. Weatherall, D.J. (2012) The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Reviews, 26, S3-S6.